LEGN – legend biotech corporation - american depositary shares (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

LEGN

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/12

12:14 pm

legn

Rating for LEGN

Low Report

Rating for LEGN

Report

12/12

12:14 pm

legn

Rating for LEGN

Low Report

Rating for LEGN

Report

12/8

11:02 am

legn

Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Medium Report

Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

12/8

11:02 am

legn

Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Medium Report

Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

12/8

10:16 am

legn

Rating for LEGN

Low Report

Rating for LEGN

Report

12/8

08:13 am

legn

Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at UBS Group AG.

Medium Report

Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at UBS Group AG.

Report

11/26

07:03 am

legn

Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Low Report

Legend Biotech (NASDAQ:LEGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

11/13

03:27 pm

legn

Rating for LEGN

Report

Rating for LEGN

Report

11/13

03:27 pm

legn

Rating for LEGN

Report

Rating for LEGN

Report

11/13

12:35 pm

legn

Rating for LEGN

Low Report

Rating for LEGN

Report

11/13

12:35 pm

legn

Rating for LEGN

Low Report

Rating for LEGN

Report

11/13

09:07 am

legn

Rating for LEGN

Low Report

Rating for LEGN

Report

10/9

09:44 am

legn

Rating for LEGN

Low Report

Rating for LEGN

Report

10/7

09:13 am

legn

Legend Biotech (NASDAQ:LEGN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $40.00 price target on the stock.

Low Report

Legend Biotech (NASDAQ:LEGN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $40.00 price target on the stock.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.